

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Empagliflozin for treating chronic kidney disease ID6131**

**Provisional Stakeholder List**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Boehringer Ingelheim (empagliflozin)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Diabetes Research and Wellness Foundation</li> <li>• Diabetes UK</li> <li>• Heart UK</li> <li>• InDependent Diabetes Trust</li> <li>• JDRF</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• National Kidney Federation</li> <li>• Network of Sikh Organisations</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Clinical Diabetologists</li> <li>• Association of Renal Technologists</li> <li>• British and Irish Hypertension Society</li> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Association of Urological Nurses</li> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• National Metabolic Biochemistry Network</li> <li>• Primary Care Diabetes Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutic and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Association of Renal Industries</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Diabetes UK Cymru</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Endocrine and Diabetes Society</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (dapagliflozin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Kidney and Transplant Group</li> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Society for Research in Rehabilitation</li> <li>• Wellcome Trust</li> </ul>

Provisional stakeholder list for the evaluation of empagliflozin for treating chronic kidney disease ID6131  
Issue date: November 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for DGH Nephrologists</li> <li>• Society for Endocrinology</li> <li>• St George's University Hospitals NHS Foundation Trust - London Kidney Network</li> <li>• TREND Diabetes</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Kidney Association</li> <li>• UK Renal Pharmacy Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.